AgingResearch.NewsJoin free

Akero Therapeutics

CompanyUnited StatesFounded 2017

Akero Therapeutics develops one asset, in phase 3 (Efruxifermin in mash metabolic dysfunction associated steatohepatitis). Mostly protein or enzyme acting on lipid and ceramide metabolism, KLB and FGFR1; based in the United States, founded in 2017.

1
Asset
Furthest stage
Phase 3
2
Trials
0
Signals

Pipeline

1

  • Efruxifermin

    FGF21 analog activating beta-Klotho-dependent FGF receptors to improve insulin sensitivity and lipid metabolism and reduce liver fibrosis.

    Phase 3, Protein or enzyme, Lipid and ceramide metabolism, KLB, mash metabolic dysfunction associated steatohepatitis, MASH with fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials2
  • Signals1
  • Similar companies6

Papers

Intelligence